Subject, Site & Sample Finder
Do you need more subjects from fewer sites?
Or do you need to obtain rare, hard to source samples? With your inclusion, exclusion and study criteria we can mine our databases to find optimized clinical sites or samples that will accelerate your studies timelines.
By studying the complex interconnectivity of hospital laboratories, medical procedures, physician decisions, claims data and insurance coding, we can consistently find study-specific, high-volume sites and sample repositories. Using Machaon Diagnostics’ proprietary disease algorithms and artificial intelligence (AI) tools, we can uncover sites managing large numbers of patients or samples.
Rare Disease defined:
a condition that affects less than 200,000 people in the US
-Orphan Drug Act, 1983
Leverage our relationships
Leverage our databases
Leverage our disease expertise
- Our algorithms are customized and validated for your disease
- Data mining and query using ICD-10, CPT, DRG, medication, procedure and other codes
- Disease characterization based on hospital and physician clinical practices
- Data mining of Machaon Diagnostics’ databases
- Algorithms that combine claims data analytics and therapeutic data analytics
- Samples from patients with targeted disorders
- Sample types include plasma, serum, stool, whole blood, tissue, respiratory and other samples
- On-site sample sequestration
- Certificate of analysis for samples
- Certificate of negativity
- Subject disidentification and tokenization options
- Many of our staff are trained CAP laboratory inspectors
Laboratory and CRO in 1
We invite you to leverage our clinical relationships with hospital systems, premiere academic medical centers, physicians and other labs, dating back to our founding in 2003.
Therapeutic Areas
- Advanced Genetics
- Cardiology
- Coagulation Disorders
- Complement Disorders
- COVID-19
- Hematology
- Immunology
- Nephrology
- Medical Devices
- Oncology
- Ophthalmology
- Pharmacogenomics
- Platelet Disorders
- Rare Disease
- Visitless (Virtual) Trials
We Deliver
Quickly and Efficiently
- Site lists (stratified for high volume sites)
- Physician lists (stratified for high volumes providers)
- Disidentified lab data and samples
- Data-guided Feasibility Studies
Database Mining
We use study-specific algorithms, we use study-specific Artificial Intelligence (AI) filters, and we perform Disease Pattern Recognition Studies
Violet Votin, PhD
Senior Clinical Research Scientist
Quote:
"We deliver data-driven decision support. Database mining works well if you have access to a well-curated database.”
Machaon Diagnostics’ databases contain over 1 Billion lines of constantly updating, healthcare data.
| BS | St. John's University |
|---|---|
| PhD | Stanford University School of Medicine |
| Post-doctoral Fellow | University of California, Berkeley |
Violet Votin, PhD
Jihyun Moon, PhD
Jihyun Moon, PhD
Senior Clinical Research Scientist
Jihyun leads the design and validation of new genetic panels. She also analyzes the NGS data and writes the clinical reports for many of our panels. Jihyun is a subject matter expert on the genetics of bleeding, clotting and platelet disorders.
Before joining Machaon in 2018, Jihyun was the Chief Scientific Officer at the synthetic biology startup TAXA, Inc., where she developed a plant metabolic engineering platform. Jihyun has published her studies on the developmental biology of maize from her time in academia.
| BS | Seoul National University |
|---|---|
| MS | Seoul National University |
| PhD | University of California, Berkeley |
| Post-doctoral Scholar | University of California, Berkeley |
Our Business Process
Client
Inquiry
Study
Quote
Breakdown
Master Service
Agreement
Work Order
Service
Examples of Our Disease Experience
- Atypical Hemolytic Uremic Syndrome (aHUS)
- Antiphospholipid Syndrome (APS)
- Coagulopathy defects
- Complement-mediated Disorders
- COVID-19
- Dysfibrinogenemia
- Hemophilia
- Heparin Allergy (HIT)
- Idiopathic Thrombocytopenia Purpura (ITP)
- Platelet Aggregation Defects
- Platelet Defects
- Storage Pool Defects
- Age-related Macular Degeneration
- Alport Syndrome
- Cancer
- C3 Glomerular Nephritis (C3G)
- Chronic Kidney Disease (CKD)
- Duchenne’s Muscular Dystrophy
- Focal segmental glomerulosclerosis (FSGS)
- Hemophagocytic Lymphohistiocytosis (HLH)
- Polycystic Kidney Disease (PKD)
- Thrombotic Microangiopathy (TMA)
- Thrombotic Thrombocytopenic Purpura (TTP)
- von Willebrand Disease
Our Work in the Scientific Literature:
Chertow, GM. Et al. Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome.
Am J Nephrol 2021;52:180–189.
Godara, A. et al. Use of Eculizumab in Transplant-Associated Thrombotic Microangiopathy in a Patient With Polycystic Kidney Disease Immediately Post–Kidney Transplant: A Case Report Author links open overlay panel.
Kidney Medicine 2020;2(5):652-656.
Tao J. et al. A rare case of Alport syndrome, atypical hemolytic uremic syndrome and Pauci-immune crescentic glomerulonephritis.
BMC Nephrology. 2018;19:355.
Challenge Us.
Click here to see examples of our Innovative Trial Solutions that we have created for clients.
Need our expertise?
-only 3% of pharmaceutical drugs make it to market. Click here to send us an inquiry.